Global pharmaceutical major Lupin Limited announced the launch of Vilfuro-G, the world’s first fixed-dose triple combination drug (FDC). As per the company’s exchange filing on Thursday (November 23, 2023), the drug will aid the effective management of chronic obstructive pulmonary disease (COPD) in India.
The approval of Vilfuro-G has been granted by the Drug Controller General of India for the Dry Powder Inhaler (DPI) product.
Lupin Launches COPD Treatment in India
The FDC combines Vilanterol, Fluticasone Furoate and Glycopyrronium bromide, for the long-term management and treatment of moderate to severe COPD.
The product is available in a single-strength fixed dose, with a recommended once-daily dosage. The new drug is likely to help the recovery of more than 37 million individuals struggling with COPD in India, a condition that ranks among the leading causes of death and disability in the nation.
Nilesh Gupta, Managing Director, Lupin said, “We are delighted to introduce Vilfuro-G, a testament to our commitment to our patients and our focus on innovation. This milestone reinforces our resolve to expanding our respiratory portfolio, providing COPD patients with access to healthcare solutions, and transforming lives.”
Rajeev Sibal, President – India Region Formulations, Lupin, added, “As the global prevalence of COPD continues to surge, India bears a significant 18% of this disease burden. With our extensive respiratory portfolio and the approval of Vilfuro-G, we take immense pride in offering healthcare professionals and patients with innovative treatment solutions.”
(The article is published under a mutual content partnership arrangement between The Free Press Journal and Connected to India)
